Immunic (IMUX)
(Real Time Quote from BATS)
$1.26 USD
+0.04 (3.28%)
Updated Apr 29, 2024 10:54 AM ET
3-Hold of 5 3
F Value A Growth B Momentum C VGM
Balance Sheet
Fiscal Year End for Immunic, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 47 | 116 | 87 | 127 | 29 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 6 | 9 | 18 | 6 | 3 |
Total Current Assets | 53 | 126 | 105 | 134 | 32 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 33 | 33 | 33 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 54 | 128 | 139 | 168 | 66 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 5 | 4 | 4 | 4 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 19 | 8 | 7 | 4 | 3 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 1 | 1 | 0 | 1 |
Total Current Liabilities | 25 | 13 | 11 | 8 | 7 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 25 | 14 | 12 | 9 | 8 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 436 | 428 | 324 | 267 | 120 |
Retained Earnings | -411 | -317 | -197 | -104 | -60 |
Other Equity | 4 | 3 | 0 | -4 | -1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 29 | 114 | 127 | 159 | 58 |
Total Liabilities & Shareholder's Equity | 54 | 128 | 139 | 168 | 66 |
Total Common Equity | 29 | 114 | 127 | 159 | 58 |
Shares Outstanding | 45.10 | 44.30 | 26.20 | 20.70 | 10.10 |
Book Value Per Share | 0.64 | 2.57 | 4.85 | 7.67 | 5.78 |
Fiscal Year End for Immunic, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 47 | 60 | 77 | 97 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 6 | 6 | 9 | 9 |
Total Current Assets | NA | 53 | 65 | 87 | 107 |
Net Property & Equipment | NA | 0 | 0 | 0 | 0 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 54 | 67 | 89 | 109 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 5 | 3 | 5 | 5 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 19 | 14 | 13 | 10 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 1 | 1 | 1 | 1 |
Total Current Liabilities | NA | 25 | 18 | 18 | 16 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 25 | 19 | 19 | 18 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 436 | 434 | 432 | 430 |
Retained Earnings | NA | -411 | -389 | -367 | -343 |
Other Equity | NA | 4 | 4 | 4 | 4 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 29 | 48 | 69 | 91 |
Total Liabilities & Shareholder's Equity | NA | 54 | 67 | 89 | 109 |
Total Common Equity | 0 | 29 | 48 | 69 | 91 |
Shares Outstanding | 89.90 | 45.10 | 44.60 | 44.60 | 44.40 |
Book Value Per Share | 0.00 | 0.64 | 1.09 | 1.55 | 2.05 |